Cancer Health Outcomes and Control Research Program

Vanderbilt University Medical Center, Nashville TN

Investigators

Linked publications, trials & patents

Abstract

PROJECT 008 ? CANCER HEALTH OUTCOMES AND CONTROL RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT The overarching mission of the Cancer Health Outcomes and Control Research Program (CO) is to foster research that can engage and reach out to the catchment area community to reduce the public health burden of cancer across the entire care continuum and to improve health-related outcomes for those at risk for or with a diagnosis of cancer. This research, which spans basic, clinical and population-based science across the cancer care continuum. can be broadly categorized into three thematic domains: 1) prevention and early detection; 2) patient-centered health outcomes during and following cancer treatment; and 3) implementation of healthcare interventions and policy to improve cancer care delivery and decrease cancer health disparities. CO will conduct research across these three domains through the following Specific Aims: Aim 1. Identify and evaluate strategies targeted to cancer prevention and early detection and develop and test behavioral- and laboratory-based interventions in healthy and at-risk populations Aim 2. Assess and compare patient-centered outcomes during and following cancer therapy in order to inform development of treatment strategies that best balance efficacy with toxicity Aim 3. Develop and implement healthcare interventions and policies on a population, practice or individual level that improve access to and delivery of care to minimize the burden of cancer in the VICC catchment area and nationally Alongside these scientific aims, the Program will develop opportunities to promote intra- and inter-programmatic research, training and mentorship with engagement of and outreach to the VICC community in a bidirectional manner to meet its mission. There are 29 program members from 14 departments and 5 schools with $8.9M in total peer-reviewed funding and NCI making up 47% ($4.2M). Out of 477 publications, 15% are intra-programmatic and 19% are inter- programmatic. Members also have 257 collaborative publications with investigators at other NCI-designated cancer centers.